Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries (TOBA II BTK)

Trial Purpose and Description

This is a prospective, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System in the Mid/Distal Popliteal, Tibial, and Peroneal Arteries ranging in diameter from 1.5mm to 4.5mm for the treatment of post percutaneous transluminal balloon angioplasty (PTA) dissection(s) requiring repair.

Ages: 18 years and older

Gender: Both

Eligibility Criteria

Inclusion Criteria:

  • Males or non-pregnant females ≥ 18 years of age at the time of consent
  • Female subjects of childbearing potential must have a negative pregnancy test prior to treatment and must use some form of contraception (abstinence is acceptable) through the duration of the study
  • Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the informed consent form (ICF), an impartial witness may sign on behalf of the subject
  • Willing to comply with all required follow-up visits
  • Rutherford Classification 4 or 5.
  • WIfI Wound grade of 0, 1 or modified 2.
  • WIfI Foot Infection grade of 0 or 1.
  • Estimated life expectancy ≥1 year

Exclusion Criteria:

  • Is pregnant or refuses to use contraception through the duration of the study
  • Previous bypass graft in the target limb
  • Acute limb ischemia, defined as symptom onset occurring less than 14 days prior to the index procedure
  • Prior or planned above-ankle amputation or complete transmetatarsal amputation to the target limb (this does not apply to ray amputation of ≤2 digits, simple digital amputations or ulcer debridements)
  • WIfI Foot Infection grade 2 or 3
  • Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)≥12,000/or febrile state
  • Endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) to the target limb less than 30 days prior to or planned for less than 30 days after the index procedure
  • Existing stent implant in the target vessel
  • Any other endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) less than 14 days prior to the index procedure or planned procedure less than 30 days after the index procedure
  • Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80,000/microliter or greater than 500,000/microliter
  • WIfI Wound grade of 2 or 3.
  • Any subject in which antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated
  • Myocardial infarction, coronary thrombolysis or angina less than 30 days prior to the Index Procedure
  • History of stroke or transient ischemic attack (TIA) less than 90 days prior to the Index Procedure
  • Currently on dialysis
  • Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)
  • Participating in another ongoing investigational clinical trial in which the subject has not completed the primary endpoint(s)
  • Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments
  • Known hypersensitivity or allergy to contrast agents that cannot be medically managed
  • Subject already enrolled into this study
  • Restenotic target lesion previously treated by means other than plain balloon angioplasty and/or less than 1 year prior to index procedure.

Intact Vascular, Inc.

Start Date: 01/02/2018

End Date: 10/31/2020

Last Updated: 02/22/2018

Study HIC#: 2000021317

Get Involved

For more information about this study, contact:
Jacqueline Marie Gamberdella
+1 203-737-1899

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Robert A Attaran

Principal Investigator